protalix.com Open in urlscan Pro
185.70.250.163  Public Scan

Form analysis
0 forms found in the DOM

Text Content

   


 * 

 * Site map
 * Contact

 * Home
 * About
   
   * About Protalix
   * Elelyso®
   * Management
   * Board of Directors
   * Scientific Advisory Board
   * Environmental Monitoring
   * Careers
 * Technology
   
   * ProCellEx® Platform
   * Orally Delivered Proteins
   * Concept to Market
 * Pipeline
   
   * Pipeline Overview
   * Pegunigalsidase alfa
   * Expanded Access
 * Publications
 * Investors
   
   * Overview
   * Press Releases
   * Stock Information
   * Financial Fundamentals
   * Presentations
   * Analyst Coverage
   * SEC filings
   * Corporate Governance
   * FAQ
   * Event Calendar
   * Contacts
 * Collaborations


 * Home
 * About
   * About Protalix
   * Elelyso®
   * Management
   * Board of Directors
   * Scientific Advisory Board
   * Environmental Monitoring
   * Careers
 * Technology
   * ProCellEx® Platform
   * Orally Delivered Proteins
   * Concept to Market
 * Pipeline
   * Pipeline Overview
   * Pegunigalsidase alfa
   * Expanded Access
 * Publications
 * Investors
   * Overview
   * Press Releases
   * Stock Information
   * Financial Fundamentals
   * Presentations
   * Analyst Coverage
   * SEC filings
   * Corporate Governance
   * FAQ
   * Event Calendar
   * Contacts
 * Collaborations


PLANT-BASED  PROTEINS  WITH
BETTER THERAPEUTIC PROFILES

Protalix is dedicated to bringing to market recombinant therapeutic proteins
with clinically improved profiles, produced with our ProCellEx® plant cell-based
expression system

Learn more
Plant-Based  Proteins  with
Better Therapeutic Profiles Protalix is dedicated to bringing to market
recombinant therapeutic proteins with clinically improved profiles, produced
with our ProCellEx® plant cell-based expression system Learn more


 * TECHNOLOGY
   
   Learn more about our ProCellEx® plant cell-based protein expression system.


 * PEGUNIGALSIDASE ALFA
   
   Pegunigalsidase alfa (PRX-102) is in Phase III for the treatment of Fabry
   disease.


 * ALIDORNASE ALFA
   
   alidornase alfa (PRX-110) is being developed for inhaled indications in
   respiratory diseases.


 * CLINICAL STUDIES ENROLLMENT COMPLETED
   
   We have competed enrollment for all our clinical studies.
   
   Learn More


 * COLLABORATE WITH PROTALIX
   
   We are actively seeking collaborations for our existing pipeline or in
   developing new therapeutic proteins
   
   Contact us





 

CORPORATE PRESENTATION

PLX Corporate Presentation (May 2024)

READ THE LATEST INTERVIEWS WITH PROTALIX'S CEO

December 2019:
PharmasAlmanac

October 2019:
BioWorld

About
 * About Protalix
 * Management
 * Board of Directors
 * Scientific Advisory Board

Technology
 * ProCellEx® Platform
 * From Concept to Market

Pipeline
 * Pipeline
 * Pegunigalsidase alfa (PRX-102)
 * Expanded Access

Contact
 * Contact Us
 * Collaborations

 * Home
 * About
 * Technology
 * Pipeline
 * Investors
 * Contact

© 2024 Plant-Based Proteins with Better Therapeutic Profiles

 * |
 * Privacy Policy
 * |
 * Terms of use

Site by CadenSee - Let's Talk Medical